Effect of lenvatinib (E7080) on the QTc interval: Results from a thorough QT study in healthy volunteers

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1109-1117

  Shumaker, Robert C ^a   Zhou, Meijian ^b   Ren, Min ^a   Fan, Jean ^a   Martinez, Gresel ^a   Aluri, Jagadeesh ^a   Darpo, Borje ^b,c  

^a EISAI INC   (United States)

^b ICardiac Technologies   (United States)

^c DANDERYD HOSPITAL   (Sweden)

Author keywords

Arrhythmia; Healthy volunteers; Oncology; QT; Thorough QT study

Indexed keywords

LENVATINIB; MOXIFLOXACIN; PLACEBO;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DYSMENORRHEA; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; OROPHARYNX PAIN; PARESTHESIA; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; T WAVE;

ADULT; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; PHENYLUREA COMPOUNDS; QUINOLINES; YOUNG ADULT;

EID: 84903817697     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2444-6     Document Type: Article

References (28)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
2. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664-671 (Pubitemid 350308963)
3. Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T (2011) Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 17:2528-2537
4. Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, Schellens JH, Evans TR (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106:1598-1604
5. Shah R (2002) The significance of QT interval in drug development. Br J Clin Pharmacol 54:188-202
6. Shah R (2002) Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 16:119-124
7. Shah R (2002) Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 16:147-156
8. Food and Drug Administration, HHS (2005) International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist 70:61134-61135
9. Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157(827-836):e1
10. Garnett CE, Zhu H, Malik M, Fossa A, Zhang J, Badilini F, Li J, Darpö B, Sager P, Rodriguez I (2012) Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am Heart J 163:912-930
11. Couderc JP, Garnett C, Li M, Handzel R, McNitt S, Xia X, Polonsky S, Zareba W (2011) Highly automated QT measurement techniques in 7 thorough QT studies implemented under ICH E14 guidelines. Ann Noninvasive Electrocardiol 16:13-24
12. E14 Implementation Working Group (2012) ICH E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions & answers (R1). http://www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Q-As-R1- step4.pdf. Accessed 23 May 2013
13. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9:811-818 (Pubitemid 20343989)
14. Florian JA, Tornøe CW, Brundage R, Parekh A, Garnett CE (2011) Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol 51:1152-1162
15. Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornøe CW, Wang Y, Zhu H, Gobburu JV (2008) Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48:13-18 (Pubitemid 350292272)
16. Lesimple T, Edeline J, Carrothers TJ, Cvitkovic F, Darpo B, Delord JP, Léna H, Penel N, Edwards GJ, Law K, Wanders J, Kristensen A, Reyderman L (2013) A phase I, open-label, singlearm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. Invest New Drugs 31:900-909
17. Bello CL, Rosen LS, Mulay M, van Vugt A, Dinolfo M, Levine S, Huang X, Fingert HJ, Toh M, Baum CM (2007) Characterization of electrocardiographic QTc interval in patients (pts) with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Eur J Cancer (suppl; abstr 709)
18. Krishnaswami S, Kudlacz E, Wang R, Chan G (2011) A supra-therapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants. J Clin Pharmacol 51:1256-1263
19. Abbas R, Hug BA, Leister C, Sonnichsen D (2012) A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer 131:E304-E311
20. Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK (2006) Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol 46:598-612
21. Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67:751-764
22. Shumaker R, Aluri J, Fan J, Martinez G, Ren M, Chen K. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers, Int J Clin Pharmacol Ther (accepted)
23. Dubbelman et al. Poster presented at the Scientific Meeting of the Dutch Society of Clinical Pharmacology & Biopharmacy (NVKFB), 30 March 2012, Utrecht, The Netherlands
24. Shumaker R et al. Poster presented at the 24th EORTC-NCIACR Symposium on Molecular Targets and Cancer Therapeutics, 6-9 November 2012, Dublin, Ireland
25. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003 BP Revision 1
26. Garnett CE, Zhu H, Malik M, Fossa A, Zhang J, Badilini F, Li J, Darpö B, Sager P, Rodriguez I (2012) Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am Heart J 163:912-930
27. Darpo B, Fossa A, Couderc JP, Zhou M, Schreyer A, Ticktin M, Zapesochny A (2011) Improving the precision of QT measurements. Cardiol J 18:401-410
28. Shumaker R, Fan J, Martinez G, Chen K (2012) Comparative bioavailability study of a 10 mg capsule and a 10 mg tablet of lenvatinib (E7080) in healthy subjects. In 113th ASCPT Annual Meeting 2012; 12-17 March; National Harbor